Search
for
Sort by
Research 661–690 of 1000+
- Biomarkers in alopecia Areata: A systematic review and meta-analysis.
- Correlation between increased total serum IgE levels and clinical features in alopecia areata patients
- LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
- 436 Allergic contact dermatitis stimulates hair follicle stem cells via macrophage-mediated regulation
- LB923 A matched cohort study evaluating the risk of keloid development in alopecia areata patients
- 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
- Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
- A bibliometric analysis of T cell and atherosclerosis
- Alopecia Areata: An Updated Review for 2023
- Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata
- 649 Gut microbiota plays a role in the development of alopecia areata
- Osteopontin: a new facilitating factor in alopecia areata pathogenesis?
- Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata
- Osteopontin Gene Polymorphisms rs1126616 C>T and rs1126772 A>G are Associated with Atopic Dermatitis in Polish Population
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
- 51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
- 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
- Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells of a Healthy Donor on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata: Targeting Dysregulated T Cells and the Acquisition of Immunotolerance
- Intralesional methotrexate in patchy alopecia areata: trichoscopic evaluation and effect on lesional tumour necrosis factor alpha
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- The Role of Vitamin D in Autoimmune Thyroid Diseases: From Immunomodulation to Clinical Implications
- Real-world evidence in alopecia areata treatment: A narrative review
- Exploring the hair follicle immune privilege state in nonsegmental vitiligo
- Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
- ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Mite Burden and Immunophenotypic Response to <i>Demodex musculi</i> in Swiss Webster, BALB/c, C57BL/6, and NSG Mice
- Phototherapy for alopecia areata